Tilray Brands (TLRY) Q1 FY27 earnings call

Tilray is positioning itself as a diversified global platform rather than a US-reform cannabis story, with BrewDog and European medical cannabis supplying growth and margin mix. Profitability still lags revenue because of price compression, fuel costs and interest, so the second-half-weighted year and cost actions carry the reaffirmed outlook.